Nektar Therapeutics Shares Slide After $400 Million Upsized Equity Offering
Nektar Therapeutics priced an upsized $400 million public offering, selling common stock and pre-funded warrants, and granted underwriters an option to buy additional shares. The move preceded a near 7% decline in premarket trading as investors reacted to the equity raise. Proceeds will support general corporate needs, including Phase 3 trials and …